How next-generation sequencing will change the treatment of multiple myeloma

Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France discusses the impact of next-generation sequencing (NGS) on the treamtment of multiple myeloma (MM). First, NGS may be used to assess the prognosis for patients in future. It may also be used to identify molecular targets for individual patients and help physicians choose the right drug for their patient. According to Prof Avet-Loiseau, it may also be used for the assessment of minimal residual disease (MRD).
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.